Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.42|
|52 Week High||US$0.38|
|52 Week Low||US$1.30|
|1 Month Change||-12.04%|
|3 Month Change||-21.11%|
|1 Year Change||0.33%|
|3 Year Change||-54.38%|
|5 Year Change||-17.22%|
|Change since IPO||-99.99%|
Recent News & Updates
|PTN||US Biotechs||US Market|
Return vs Industry: PTN underperformed the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: PTN underperformed the US Market which returned 30% over the past year.
Stable Share Price: PTN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: PTN's weekly volatility has decreased from 13% to 7% over the past year.
About the Company
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.
Palatin Technologies Fundamentals Summary
|PTN fundamental statistics|
Is PTN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PTN income statement (TTM)|
|Cost of Revenue||US$13.07m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.15|
|Net Profit Margin||17,813.91%|
How did PTN perform over the long term?See historical performance and comparison
Is Palatin Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PTN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PTN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PTN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: PTN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PTN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PTN is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (2.9x).
How is Palatin Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PTN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PTN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PTN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PTN's revenue (35.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: PTN's revenue (35.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PTN's Return on Equity is forecast to be high in 3 years time
How has Palatin Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PTN is currently unprofitable.
Growing Profit Margin: PTN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PTN is unprofitable, but has reduced losses over the past 5 years at a rate of 16.7% per year.
Accelerating Growth: Unable to compare PTN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: PTN has a negative Return on Equity (-67.66%), as it is currently unprofitable.
How is Palatin Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: PTN's short term assets ($65.9M) exceed its short term liabilities ($10.5M).
Long Term Liabilities: PTN's short term assets ($65.9M) exceed its long term liabilities ($7.1M).
Debt to Equity History and Analysis
Debt Level: PTN is debt free.
Reducing Debt: PTN currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PTN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PTN has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 26.1% each year.
What is Palatin Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PTN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PTN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PTN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PTN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PTN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carl Spana (59 yo)
Dr. Carl Spana, Ph D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief...
CEO Compensation Analysis
Compensation vs Market: Carl's total compensation ($USD2.29M) is above average for companies of similar size in the US market ($USD545.22K).
Compensation vs Earnings: Carl's compensation has increased whilst the company is unprofitable.
Experienced Management: PTN's management team is seasoned and experienced (10.8 years average tenure).
Experienced Board: PTN's board of directors are seasoned and experienced ( 16.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Palatin Technologies, Inc.'s employee growth, exchange listings and data sources
- Name: Palatin Technologies, Inc.
- Ticker: PTN
- Exchange: NYSEAM
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$97.637m
- Shares outstanding: 231.26m
- Website: https://palatin.com
Number of Employees
- Palatin Technologies, Inc.
- Cedar Brook Corporate Center
- 4B Cedar Brook Drive
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 23:34|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.